Clinical efficacy and failure pattern in patients with cervical esophageal cancer treated with definitive chemoradiotherapy

Patterns of failure and clinical outcomes of definitive radiotherapy for cervical esophageal cancer

“…We also found that regional failure sites were mainly located in the supraclavicular area (62.5%, 5/8) and all of them failed outside of CTV if they were not prophylactically covered (or so-called “electively treated”). Moreover, our study showed that, hoarseness, which is the main clinical manifestations caused by RLN tumor invasion or RLN compression, was an independent prognostic factor for OS, which was also reported in another study [18]. Therefore, the RLN chains and supraclavicular/cervical region treatment should be prophylactically covered if not already involved, as evidenced by the fact that patients receiving ENI had significantly better RFFS than those receiving IFI.…”

“…Local-regional failure rates are high for CEC after definitive radiotherapy or chemoradiotherapy, with the local control rate of approximately 58-68% [14, 18]. For our study, the 3-year LRFFS was 58% and 24% of the patients experienced loco-regional failure at the last follow up, which was the major failure pattern.…”

“…In some older series, the typical 3-year OS rate was less than 35% [17]. In more modern series, the 3-year OS rates appear to have been improved to nearly 40% [18, 19]. In the current study, the reported 3-year OS was 53.6%, suggesting that in the modern era, the employment of multiple multidisciplinary advances, including possibly advances in RT techniques, may play roles in improving outcomes of CEC [20, 21].…”

Combination of graphene oxide–silver nanoparticle nanocomposites and cisplatin enhances apoptosis and autophagy in human cervical cancer cells

“…Radiotherapy or chemoradiotherapy is often used for patients with advanced-stage cervical cancer. 9,10 Chemotherapy seems to be a powerful therapeutic approach for the treatment and management of cancer, which is also supplementing other strategies such as surgery and radiation therapy. 11 Among the various chemical reagents used in chemotherapy, such as cisplatin (Cis), carboplatin, paclitaxel, topotecan, gemcitabine, the platinum-based chemical reagents are most commonly used.…”

“…11 Among the various chemical reagents used in chemotherapy, such as cisplatin (Cis), carboplatin, paclitaxel, topotecan, gemcitabine, the platinum-based chemical reagents are most commonly used. 9 The anticancer efficacies of current therapies are limited, due to the high degree of cancer clonal heterogeneity and drug resistance. In addition, using a single therapeutic agent is not effective in eradicating cancer cells, and hence the use of combinatorial therapy, which could inhibit multiple targets or redundant pathways simultaneously, is essential and inevitable.…”